+

WO2000044408A3 - Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1 - Google Patents

Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1 Download PDF

Info

Publication number
WO2000044408A3
WO2000044408A3 PCT/US2000/002124 US0002124W WO0044408A3 WO 2000044408 A3 WO2000044408 A3 WO 2000044408A3 US 0002124 W US0002124 W US 0002124W WO 0044408 A3 WO0044408 A3 WO 0044408A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory disease
ccr1 antagonists
treating demyelinating
demyelinating inflammatory
treating
Prior art date
Application number
PCT/US2000/002124
Other languages
English (en)
Other versions
WO2000044408A2 (fr
Inventor
James B Rottman
Wayne W Hancock
Original Assignee
Leukosite Inc
James B Rottman
Wayne W Hancock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leukosite Inc, James B Rottman, Wayne W Hancock filed Critical Leukosite Inc
Priority to AU27409/00A priority Critical patent/AU2740900A/en
Priority to EP00905778A priority patent/EP1148889A2/fr
Priority to JP2000595710A priority patent/JP2002535376A/ja
Priority to CA002361256A priority patent/CA2361256A1/fr
Publication of WO2000044408A2 publication Critical patent/WO2000044408A2/fr
Publication of WO2000044408A3 publication Critical patent/WO2000044408A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à une méthode de traitement des troubles inflammatoires démyélinisants. Cette méthode consiste à administrer à un sujet nécessitant un tel traitement une quantité efficace d'un antagoniste de la fonction CCR1. Dans une réalisation préférée, l'invention se rapporte à une méthode de traitement de la sclérose en plaques.
PCT/US2000/002124 1999-01-29 2000-01-27 Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1 WO2000044408A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU27409/00A AU2740900A (en) 1999-01-29 2000-01-27 Method of treating demyelinating inflammatory disease using ccr1 antagonists
EP00905778A EP1148889A2 (fr) 1999-01-29 2000-01-27 Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1
JP2000595710A JP2002535376A (ja) 1999-01-29 2000-01-27 Ｃｃｒ１アンタゴニストを用いた脱髄性炎症性疾患の治療方法
CA002361256A CA2361256A1 (fr) 1999-01-29 2000-01-27 Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24025399A 1999-01-29 1999-01-29
US09/240,253 1999-01-29

Publications (2)

Publication Number Publication Date
WO2000044408A2 WO2000044408A2 (fr) 2000-08-03
WO2000044408A3 true WO2000044408A3 (fr) 2000-12-14

Family

ID=22905789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002124 WO2000044408A2 (fr) 1999-01-29 2000-01-27 Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1

Country Status (5)

Country Link
EP (1) EP1148889A2 (fr)
JP (1) JP2002535376A (fr)
AU (1) AU2740900A (fr)
CA (1) CA2361256A1 (fr)
WO (1) WO2000044408A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
MY157727A (en) 2002-02-25 2016-07-15 Biogen Idec Inc Administration of agents for the treatment of inflamation
PT1494703E (pt) 2002-04-04 2006-05-31 Applied Research Systems Quimiocinas mutantes que apresentam uma disponibilidade biologica oral melhorada
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
CA2514117A1 (fr) 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition et methode destinees a traiter les maladies de demyelinisation et la paralysie par administration d'agents de remyelinisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024325A1 (fr) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
JPH09249566A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ピペリジン化合物含有ケモカイン受容体拮抗剤
JPH09249570A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ベンゾジアゼピン化合物含有ケモカイン受容体拮抗剤
WO1998038167A1 (fr) * 1997-02-26 1998-09-03 Pfizer Inc. Derives amines de l'acide heteroaryle-hexanoique, leur preparation, et leur utilisation comme inhibiteurs selectifs du mip-1 alpha par fixation a son recepteur ccr1
WO1998056771A2 (fr) * 1997-06-12 1998-12-17 Schering Aktiengesellschaft Derives de piperazine et leur utilisation en tant qu'agents anti-inflammatoires

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024325A1 (fr) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
JPH09249566A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ピペリジン化合物含有ケモカイン受容体拮抗剤
JPH09249570A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ベンゾジアゼピン化合物含有ケモカイン受容体拮抗剤
WO1998038167A1 (fr) * 1997-02-26 1998-09-03 Pfizer Inc. Derives amines de l'acide heteroaryle-hexanoique, leur preparation, et leur utilisation comme inhibiteurs selectifs du mip-1 alpha par fixation a son recepteur ccr1
WO1998056771A2 (fr) * 1997-06-12 1998-12-17 Schering Aktiengesellschaft Derives de piperazine et leur utilisation en tant qu'agents anti-inflammatoires

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199748, Derwent World Patents Index; Class B02, AN 1997-521868, XP002139271 *
DATABASE WPI Section Ch Week 199804, Derwent World Patents Index; Class B03, AN 1998-035793, XP002139272 *
HESSELGESSER ET AL.: "Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor", J. BIOLOGICAL CHEMISTRY, vol. 273, no. 25, 19 June 1998 (1998-06-19), pages 15687 - 15692, XP000887384 *

Also Published As

Publication number Publication date
CA2361256A1 (fr) 2000-08-03
EP1148889A2 (fr) 2001-10-31
WO2000044408A2 (fr) 2000-08-03
JP2002535376A (ja) 2002-10-22
AU2740900A (en) 2000-08-18

Similar Documents

Publication Publication Date Title
WO2002055017A3 (fr) Methode de traitement de maladies auto-immunes
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
WO1999064059A3 (fr) Utilisation de la secretine pour le traitement de l'autisme et d'autres troubles du comportement, troubles neurologiques ou immunologiques
WO2004100898A3 (fr) Utilisation therapeutique d'anticorps anti-cs1
WO2002100390A3 (fr) Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain
HUP0003386A3 (en) Use of crf antagonists for the preparation of pharmaceutical compositions treating depression, cardiovascular diseases
AU2003248245A1 (en) Remedies for diseases caused by vascular contraction or dilation
WO2000064441A3 (fr) Medicament
CA2311356A1 (fr) Procede pour le traitement de la maladie d'alzheimer
PL331922A1 (en) Method of inhibiting fibrosis by means of an antagonist of somatotropin release inhibiting factor
WO2001009138A3 (fr) Antagonistes du recepteur de chimiokine et procedes d'utilisation associes
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
SI1562954T1 (sl) CCR1 antagonisti za zdravljenje med drugim demielinirne vnetne bolezni
EP1399151A4 (fr) Procede de traitement de maladies inflammatoires par administration d'un agoniste ppar-delta
WO2001001972A3 (fr) ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
WO2000027850A3 (fr) Antagonistes de recepteurs du crf et methodes associees
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
WO2004002421A3 (fr) Procede de traitement de la sclerose en plaques
AU8893098A (en) Immuno-modulator exhibiting anti-microbial and anti-mycobacterial activities, method for producing the same and pharmaceutical preparation for treating mycobacterioses as well as lung chronic and non specific conditions, sexually transmitted diseases and the resulting
ID30117A (id) Antagonis 5ht1 untuk terapi anti depresan
WO2000044408A3 (fr) Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1
GB9907571D0 (en) Compounds
EP0799618A3 (fr) Utilisation d'antagonistes de l'adrénorécepteur alpha 1 dans la fabrication d'unmédicament pur la prévention et au traitment du cancer
MXPA01003761A (es) Agente para tratar oftalmopatia.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 27409/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007565

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2361256

Country of ref document: CA

Ref country code: CA

Ref document number: 2361256

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 595710

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000905778

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000905778

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000905778

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载